Christopher Raymond Analyst Performance

Analyst at Piper Sandler

Christopher Raymond is a stock analyst at Piper Sandler in the medical sector, covering 20 publicly traded companies. Over the past year, Christopher Raymond has issued 14 stock ratings, including buy and hold recommendations. While full access to Christopher Raymond's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Christopher Raymond's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 52 Last 10 Years
Buy Recommendations: 72.00% 36 Buy Ratings
Companies Covered: 20 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	2.0%	1 ratings
Buy	70.0%	35 ratings
Hold	26.0%	13 ratings
Sell	2.0%	1 ratings

Out of 50 total stock ratings issued by Christopher Raymond at Piper Sandler, the majority (70.0%) have been Buy recommendations, followed by 26.0% Hold, 2.0% Strong Buy, and 2.0% Sell.

Best & Worst Calls

Best Call
0000.0%
RARE
Dec 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ALXO
Nov 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	90.0% of companies on NASDAQ	18 companies
NYSE	10.0% of companies on NYSE	2 companies

Christopher Raymond, an analyst at Piper Sandler, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 20 companies	100.0%

Christopher Raymond of Piper Sandler specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 14 companies	70.0%
PHARMACEUTICAL PREPARATIONS 4 companies	20.0%
MED - DRUGS 1 company	5.0%
LARGE CAP PHARMA 1 company	5.0%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ARDX Ardelyx	8/6/2025	Boost Price Target	$5.09	$9.00	Neutral
ABVX Abivax	7/23/2025	Boost Price Target	$67.67	$70.00	Overweight
ITOS iTeos Therapeutics	5/14/2025	Set Price Target	$7.52	$12.00
BIIB Biogen	4/29/2025	Lower Price Target	$120.39	$115.00	Neutral
ALXO ALX Oncology	3/6/2025	Boost Price Target	$1.24	$9.00	Overweight
BMRN BioMarin Pharmaceutical	2/20/2025	Boost Price Target	$65.61	$126.00	Overweight
BIIB Biogen	2/18/2025	Reiterated Rating	$138.59	$135.00	Neutral
QTTB Q32 Bio	2/11/2025	Downgrade	$3.18	$4.00	Neutral
ARDX Ardelyx	1/27/2025	Boost Price Target	$5.69	$8.00	Neutral
BPMC Blueprint Medicines	1/27/2025	Boost Price Target	$116.60	$119.00	Neutral
VRTX Vertex Pharmaceuticals	1/27/2025	Lower Price Target	$441.51	$533.00	Overweight
REGN Regeneron Pharmaceuticals	1/27/2025	Lower Price Target	$688.17	$1,013.00	Overweight
RARE Ultragenyx Pharmaceutical	1/13/2025	Boost Price Target	$41.54	$140.00	Overweight
INZY Inozyme Pharma	1/13/2025	Lower Price Target	$1.75	$30.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.